Skip to main content
. 2019 Dec 26;14(12):e0226714. doi: 10.1371/journal.pone.0226714

Fig 4. Sensitivity to DNA damaging agents of primary tumor cells from Palb2-KPC, Brca1-KPC and Brca2-KPC solid tumors detected by karyotype analyses.

Fig 4

(A) Palb2-KPC, Brca1-KPC and Brca2-KPC pancreatic tumor cells showed increased sensitivity vs KPC tumor cells, to MMC and Olaparib. Representative images of metaphase spreads from Palb2-KPC, Brca1-KPC and Brca2-KPC pancreatic tumor cells treated with MMC. Total chromosome aberrations in individual tumors following drug treatments (Means ± SEM; ****P<0.0001, **P<0.0011). (B) Responses to specific drug treatments of cells from specific mouse strain tumors was measured by MTT assay. Exposure to each drug was for 72 hrs before the MTT assays were performed. The data are from 6 replicates of 2 tumor cells per genotype. For the Olaparib treatment, due to its short half-life, medium with fresh drug was changed every 24 hrs. (Mean ± SEM).